Transactions in relation to share buyback program

On 26 November 2019, Össur hf. initiated a share buy-back program, see Company announcement no. 72/2019.

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 11 March 2020. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions have been made under the program in week 2, the period 2 December 2019 - 6 December 2019:

Transactions

Date	No. of shares	Avg. purchase price in DKK	Transaction value in DKK
2 December 2019	14,948	52.79	789,169
3 December 2019	27,592	53,07	1,464,332
4 December 2019	1,915	53.03	101,560
5 December 2019	19,505	54.14	1,055,925
6 December 2019	9,502	54.15	514,514
Total	73,462	53.44	3,925,500

Össur has acquired 125,765 shares under the program at the average price of DKK 52.31. Following the above transactions Össur's holding of own shares is 3,106,976 corresponding to 0.73% of the Company's total share capital.

The share buyback program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.

Further information

David Hreidarsson, Investor Relations, dohreidarsson@ossur.com, +354 515 1380

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors

About Össur

Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of Prosthetics and Bracing & Supports. A recognized "Technology Pioneer," Össur invests significantly in research and product development—its award-winning designs ensuring a consistently

strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com